39.57 USD
↗ 0.07 (0.18%)AT CLOSE (11:59 AM EDT)
Roivant Sciences Ltd. Common Shares
ROIVNASDAQ • USD
40.50
↗ 0.92 (2.34%)
POST MARKET (AS OF 07:40 PM EDT)
Post Market
AS OF 07:40 PM EDT
40.50
↗ 0.92 (2.34%)
Market: CLOSED
Roivant Sciences Ltd. Common Shares (ROIV) trades at $39.56 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Sep 16, 2026.
Open?$39.77
High?$40.45
Low?$39.17
Prev. Close?$39.50
Volume?6.2M
Avg. Volume?8.1M
VWAP?$39.83
Rel. Volume?0.76x
Bid / Ask
Bid?$39.97 × 100
Ask?$41.50 × 1.8K
Spread?$1.53
Midpoint?$40.74
Valuation & Ratios
Market Cap?28.6B
Shares Out?722.3M
Float?371.0M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?6.76
EPS?-$0.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
721
Market Cap
28.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
LONDON, SW1H 0DB
Phone: 441-295-5950
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?35
Piotroski F-Score?0/9Weak
Altman Z-Score?44.91Safe
Confidence?58%Low
Short InterestElevated
Short % of Float?9.04%Elevated
Short Interest?33.5M
Days to Cover?3.8
Free Float371.0M
Avg Daily Volume8.8M
Settlement Date2026-08-31
Financial Health
Current Ratio?16.72Strong
Quick Ratio?16.72Strong
Cash Ratio?4.40Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?6.76FAIR▾
Peers100
S&P28
P/S?3,794.79HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-20.0CHEAP▾
S&P97
EV/Sales?3,629.03HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-6.3%WEAK▾
S&P10
ROA?-5.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-821063000
Enterprise Value?$27.3B
Fundamentals ratios updated end of day